

IFX-1-P2.5

Riana Peischl, Thomas Neumann, Andrea Rubbert Roth

a randomized, double-blind, double-dummy, active-controlled, multicenter, 2-part Phase 2 study on replacement of steroids by IFX-1 in active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

type of project	clinical studies
status	completed
start of project	2020
end of project	2021
study design	This is a prospective, randomized, double-blind, double-dummy, active-controlled, multicenter, 2-part Phase 2 study. a total of 3 treatment groups will be investigated: Group A: IFX-1 + reduced-dose GC Group B: Placebo-IFX-1 + standard-dose GC Group C: IFX-1 + no GC
responsible person	Dr.Thomas Neumann